Try

REGENXBIO Inc. Common Stock

RGNXUnited States

5 filed reports · 252 financial concepts · 4 earnings calls · 0 media appearances

Filed reports

5 reports · Jun 2025 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report type	Reports	Facts	Periods
Quarterly · 10-QSEC EDGAR	4	970	Jun 2025 to Jun 2026
Annual · 10-KSEC EDGAR	1	643	Dec 2025

Documents

Period	Type	Period end	Published	Facts	Source
FY2026 Q2	10-Q	Jun 30, 2026	Aug 6, 2026	394	Open
FY2026 Q1	10-Q	Mar 31, 2026	May 14, 2026	227	Open
FY2025	10-K	Dec 31, 2025	Mar 5, 2026	643	Open
FY2025 Q3	10-Q	Sep 30, 2025	Nov 6, 2025	237	Open
FY2025 Q2	10-Q	Jun 30, 2025	Aug 7, 2025	112	Open

Financial data

252 concepts · 1,613 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial249 concepts · 1,533 facts · Dec 2023 to Jun 2026

Royalty monetization liabilities24 · Dec 2024 to Jun 2026
Other unbilled14 · Dec 2024 to Jun 2026
Accounts receivable net13 · Dec 2023 to Jun 2026
Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations13 · Dec 2023 to Jun 2026
Contract with customer liability13 · Dec 2023 to Jun 2026
Stockholders equity (US GAAP)13 · Dec 2023 to Jun 2026
Adjustments to additional paid in capital sharebased compensation requisite service period recognition value11 · Jun 2024 to Jun 2026
Allocated share based compensation expense11 · Jun 2024 to Jun 2026
Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
Comprehensive income net of tax11 · Jun 2024 to Jun 2026
Contract with customer asset net current11 · Jun 2024 to Jun 2026
Cost of license and royalty revenues11 · Jun 2024 to Jun 2026
Costs and expenses11 · Jun 2024 to Jun 2026
Deferred revenue revenue recognized111 · Jun 2024 to Jun 2026
General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
Interest expense nonoperating11 · Jun 2024 to Jun 2026
Interest income from licensing11 · Jun 2024 to Jun 2026
Investment income interest11 · Jun 2024 to Jun 2026
Investment income net11 · Jun 2024 to Jun 2026
Net income loss11 · Jun 2024 to Jun 2026
Nonoperating income expense11 · Jun 2024 to Jun 2026
Operating income loss11 · Jun 2024 to Jun 2026
Other comprehensive income loss available for sale securities adjustment net of tax11 · Jun 2024 to Jun 2026

Product2 concepts · 79 facts · Jun 2024 to Jun 2026

Revenue77 · Jun 2024 to Jun 2026
Number of countries where licensed patents remain active2 · Mar 2026 to Jun 2026

Geography1 concepts · 1 facts · Dec 2025

Operating lease expiration year1 · Dec 2025

Segments

80 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service10 members · 79 facts

Zolgensma Royalties13 · Jun 2024 to Jun 2026
License And Service11 · Jun 2024 to Jun 2026
Other Service Revenue11 · Jun 2024 to Jun 2026
Service11 · Jun 2024 to Jun 2026
Total Service Revenue11 · Jun 2024 to Jun 2026
Nippon Shinyaku Services7 · Mar 2025 to Jun 2026
Zolgensma And Itvisma Royalties6 · Dec 2024 to Jun 2026
Nippon Shinyaku Licenses5 · Mar 2025 to Dec 2025
Itvisma Royalties3 · Dec 2025 to Jun 2026
Abb Vie Development Milestone1 · Jun 2026

Statement geographical1 member · 1 facts

Maryland And New York1 · Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.